<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05617846</url>
  </required_header>
  <id_info>
    <org_study_id>ZZUSC-19</org_study_id>
    <nct_id>NCT05617846</nct_id>
  </id_info>
  <brief_title>Application of Antiosteoporosis Therapy in Osteolysis</brief_title>
  <official_title>Efficacy and Safety of Antiosteoporosis Therapy in Patients After Bone Tumor Resection: a Multicenter, Real-world Prospective Cohort Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To report the postoperative complications and limb function of patients with osteolysis after&#xD;
      surgery for bone tumors of the extremities who received anti-osteoporosis therapy in Henan&#xD;
      Cancer Hospital in the next 10 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 100 patients with osteolysis after surgery for bone tumors of the four extremities&#xD;
      who received anti-osteoporosis treatment in Henan Cancer Hospital in the next 10 years were&#xD;
      reported. The basic information, treatment methods, postoperative complications and limb&#xD;
      function of these patients were collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 28, 2023</start_date>
  <completion_date type="Anticipated">November 30, 2032</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2032</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complications</measure>
    <time_frame>Collected from the beginning of treatment to 24 months after treatment.</time_frame>
    <description>The incidence of complications after anti-osteoporosis treatment was collected and the severity of complications was evaluated according to CTCAE5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Limb function</measure>
    <time_frame>Collected from the beginning of treatment to 24 months after treatment.</time_frame>
    <description>Limb function was assessed using the Musculoskeletal Oncology Society (MSTS) scoring scale for seven items, namely movement, pain, stability, deformity, strength, functional activity, and emotional receptiveness. The highest possible score is 35, with 5 points allocated to each project.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Limb; Fusion</condition>
  <condition>Complication</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <description>Patients who received antiosteoporosis therapy after bone tumor resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients who underwent bone tumor resection without antiosteoporosis therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anti-osteoporosis therapy</intervention_name>
    <description>Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving antiosteoporosis therapy for osteolysis after surgery for bone tumors in&#xD;
        the extremities&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. No age restriction, male or female.&#xD;
&#xD;
          2. A subtype of bone tumor (including benign, malignant, and metastatic cancer) was&#xD;
             confirmed in the pathology department of the research institution.&#xD;
&#xD;
          3. Received excision of bone tumor in research institution.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Not applicable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Bone and Soft Tissue ,Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tian Zhichao, Dr.</last_name>
      <phone>+8618737187831</phone>
      <email>tianzhichhaoyy@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>October 31, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>February 16, 2023</last_update_submitted>
  <last_update_submitted_qc>February 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Wang Jiaqiang</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

